133 related articles for article (PubMed ID: 32621483)
1. [Possibilities of using Mexidol in the complex therapy of mental disorders].
Shamrey VK; Kurasov ES; Nechiporenko VV; Kolchev AI; Tsygan NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(5):160-164. PubMed ID: 32621483
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia].
Zhuravleva MV; Prokofiev AB; Serebrova SY; Vasyukova NS; Demchenkova EY; Arkhipov VV
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(6):119-124. PubMed ID: 32678558
[TBL] [Abstract][Full Text] [Related]
3. [The possibilities of Mexidol usage in neuropediatrics].
Zavadenko NN; Suvorinova NY; Zavadenko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9. Vyp. 2):43-50. PubMed ID: 37942971
[TBL] [Abstract][Full Text] [Related]
4. [Improving the effectiveness of pharmacotherapy in comorbid patients with chronic cerebral ischemia on an outpatient basis].
Vizilo TL; Arefieva EG
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):51-55. PubMed ID: 36946397
[TBL] [Abstract][Full Text] [Related]
5. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
Potvin S; Stip E; Roy JY
Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain].
Chukanova EI; Chukanova AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(9):39-45. PubMed ID: 31626217
[TBL] [Abstract][Full Text] [Related]
7. [The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis].
Zakharov VV; Vakhnina NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(1):82-88. PubMed ID: 38261288
[TBL] [Abstract][Full Text] [Related]
8. [A modern concept of antihypoxic and antioxidant effects of mexidol].
Shchulkin AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(12. Vyp. 2):87-93. PubMed ID: 30830123
[TBL] [Abstract][Full Text] [Related]
9. [Possibility of application Mexidol for the treatment of patients suffering from sensorineural hearing loss and cerebrovascular insufficiency].
Kunelskaya NL; Levina YV; Yanyushkina ES; Ogorodnikov DS; Larionova EV
Vestn Otorinolaringol; 2019; 84(6):108-111. PubMed ID: 32027333
[TBL] [Abstract][Full Text] [Related]
10. [Toothpastes of the «Mexidol dent» line - parapharmaceuticals with stable antioxidative activity].
Udyanskaya IL; Slonskaya TK; Yankova VG; Romanchenko IA; Chernykh AA; Lodina AA
Stomatologiia (Mosk); 2020; 99(2):45-49. PubMed ID: 32441075
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia].
Shchepankevich LA; Nikolaev YA; Taneeva EV; Pervuninskaya MA; Shchepankevich MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10):32-37. PubMed ID: 34874652
[TBL] [Abstract][Full Text] [Related]
12. [An effect of mexidol on the expression of the transcription factor Nrf2 in the rat cerebral cortex in ischemia].
Yakusheva EN; Mylnikov PY; Chernykh IV; Shchulkin AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(5):64-68. PubMed ID: 29927406
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy of ethylmethylhydroxypyridine in the rehabilitation treatment of poststroke patients].
Zhuravleva MV; Prokofiev AB; Arkhipov VV; Serebrova SY; Gorodetskay GI; Demidova OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):92-96. PubMed ID: 32323950
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke].
Chefranova ZhIu; Makotrova TA; Udachin VA; Koledintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(4):49-52. PubMed ID: 22810741
[TBL] [Abstract][Full Text] [Related]
15. [Neuroprotection therapy of multiple sclerosis with high doses of ethylmethylhydroxypyridine succinate].
Prakhova LN; Ilves AG; Savintceva ZI; Mineev KK; Nikiforova IG; Rubanik KS; Kataeva GV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):73-78. PubMed ID: 28139615
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of blood rheology by patients with acute ischemic stroke with Mexidol administration].
Plotnikov DM; Stegmeier MN; Aliev OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3. Vyp. 2):76-82. PubMed ID: 31184628
[TBL] [Abstract][Full Text] [Related]
17. [Possibilities of antioxidant therapy for asthenia and cognitive deficit in elderly patients with chronic brain ischemia].
Duma SN
Ter Arkh; 2013; 85(12):100-5. PubMed ID: 24640678
[TBL] [Abstract][Full Text] [Related]
18. [Mexidol effect on the factor induced by hypoxia HIF-1α expression in the rat cerebral cortex in ischemia].
Yakusheva EN; Mylnikov PY; Chernykh IV; Shchulkin AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):87-91. PubMed ID: 29171495
[TBL] [Abstract][Full Text] [Related]
19. [Experience with mexidol in neurological practice].
Gromova OA; Torshin IY; Stakhovskaya LV; Pepelyaev EG; Semenov VA; Nazarenko AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):97-107. PubMed ID: 30499505
[TBL] [Abstract][Full Text] [Related]
20. [Effect of mexidol (2-ethyl-6-methyl-3-oxypyridine succinate) on the quality of life and depressive symptoms in women with rheumatoid arthritis].
Sineglazova AV; Volchegorskiĭ IA
Eksp Klin Farmakol; 2013; 76(1):7-10. PubMed ID: 23461008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
